Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.92
+$0.05 · +1.03%
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Previous close
$4.92
+$0.05 · +1.03%
Regular session · ET · Market data may be delayed.
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $4.92
52-week range
Current $4.92
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
67
Undervalued
Sentiment
41
Mixed
Risk
67
High Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $4.92
52-week range
Current $4.92
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 30.91M USD | 22.6M USD | 34.16M USD | 19.23M USD | 1.32M USD |
| Cost of goods sold | 3.33M USD | — | — | — | — |
| Gross profit | 27.58M USD | 22.6M USD | 34.16M USD | 19.23M USD | 1.32M USD |
| Research and development | 85.47M USD | 94.53M USD | 109.69M USD | 105.62M USD | 80.33M USD |
| Selling, general, and administrative | 27.55M USD | 28.36M USD | 32.37M USD | 30.75M USD | 21.73M USD |
| Operating expenses | 109.68M USD | 125.29M USD | 142.06M USD | 136.37M USD | 102.05M USD |
| Interest income | 8.75M USD | 11.9M USD | 10.88M USD | 5.68M USD | 59K USD |
| Interest expense | — | — | — | — | 1.91M USD |
| Depreciation and amortization | 3.33M USD | 3.12M USD | 3.45M USD | 3.32M USD | 3.23M USD |
| Operating income | −82.11M USD | −102.68M USD | −107.91M USD | −117.14M USD | −100.73M USD |
| Net income | −74.28M USD | −86.62M USD | −98.43M USD | −108.88M USD | −101.32M USD |
Company facts updated Sep 6, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$13.86
181.71% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM5.02M0.01%79.88B USD0.19%$296.01+0.28%
Vanguard Morningstar Total Stock Market ETFVTI4.71M0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Extended Market ETFVXF1.94M0.00%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO1.94M0.01%14.58B USD0.24%$377.54+0.12%
iShares Biotechnology ETFIBB1.32M0.01%10.72B USD0.44%$211.92-0.88%
Vanguard Russell 2000 ETFVTWO928.71K0.01%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC708.63K0.05%1.47B USD0.60%$196.25+0.69%
Invesco Russell 2000 Dynamic Multifactor ETFOMFS243.22K0.09%282.64M USD0.39%$52.595-0.03%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCInvesco Russell 2000 Dynamic Multifactor ETFOMFSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
